AstraZeneca presented detailed results from the phase III CASPIAN trial, showing IMFINZI (durvalumab) significantly improved overall survival (OS) in patients with previously-untreated extensive-stage small cell lung cancer (SCLC).
Bristol-Myers Squibb Co. announced long-term pooled efficacy and safety results from the phase III CheckMate -017 and CheckMate -057 studies in patients with previously treated advanced non-small cell lung cancer.
Eli Lilly and Co. presented data from the LIBRETTO-001 clinical trial intended to support the registration of oral selpercatinib[1] monotherapy, also known as LOXO-292, for the treatment of RET fusion-positive non-small cell lung cancer.
A new clinical guideline from the American Society for Radiation Oncology provides recommendations on the use of radiation therapy to treat patients diagnosed with pancreatic cancer, including when radiation treatments are appropriate, as well as the optimal dosing, timing and fractionation for these treatments.
A large population-based study from the Sidney Kimmel Cancer Center—Jefferson Health shows that novel oral androgen signaling inhibitor therapies are associated with an increased risk of death in patients with pre-existing cardiovascular conditions. The research was published in the journal European Urology.
Cancer patients who enroll in a clinical trial and have no health insurance, or are enrolled in Medicaid may not get the same benefits of successful trial treatments that other cancer patients do.
Mount Sinai researchers have found a new type of therapy to be effective for patients with a particular type of bone marrow cancer that is resistant to several standard therapies, according to results of a clinical trial published in The New England Journal of Medicine in August.
GlaxoSmithKline plc announced positive results from the pivotal DREAMM-2 open-label, randomized study of two doses of belantamab mafodotin (GSK2857916).
The Genomics of Drug Sensitivity in Cancer project has released the results of four years of data gathering and exploration. The freely available data set includes unique data comparing almost 1,000 cancer cell lines' responses to 453 licensed and experimental drugs.
Vermillion Inc. announced publication of a paper titled: “Clinical Performance Comparison of Two In-Vitro Diagnostic Multivariate Index Assays for Presurgical Assessment for Ovarian Cancer Risk” in the journal Advanced Therapeutics (Shulman et al. Adv Ther. July 2019).
